2024-08-01 2025-07-31 false No description of principal activity Acting Office - Tax and Accounts 1.0 14995409 bus:FullAccounts 2024-08-01 2025-07-31 14995409 bus:Micro-entities 2024-08-01 2025-07-31 14995409 bus:AuditExempt-NoAccountantsReport 2024-08-01 2025-07-31 14995409 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 14995409 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 14995409 2024-08-01 2025-07-31 14995409 2025-07-31 14995409 bus:RegisteredOffice 2024-08-01 2025-07-31 14995409 core:WithinOneYear 2025-07-31 14995409 core:AfterOneYear 2025-07-31 14995409 2023-07-11 14995409 bus:Director1 2024-08-01 2025-07-31 14995409 bus:Director1 2025-07-31 14995409 bus:Director1 2023-07-11 2024-07-31 14995409 bus:CompanySecretary1 2024-08-01 2025-07-31 14995409 bus:LeadAgentIfApplicable 2024-08-01 2025-07-31 14995409 2023-07-11 2024-07-31 14995409 2024-07-31 14995409 core:WithinOneYear 2024-07-31 14995409 core:AfterOneYear 2024-07-31 14995409 bus:EntityAccountantsOrAuditors 2023-07-11 2024-07-31 14995409 core:CostValuation core:Non-currentFinancialInstruments 2025-07-31 14995409 core:CostValuation core:Non-currentFinancialInstruments 2024-07-31 14995409 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:ShareProfitOrLossIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:ProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:ImpairmentReversalProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:ForeignExchangeDifferencesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:TransfersBetweenInvestmentClassesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14995409 core:Non-currentFinancialInstruments 2025-07-31 14995409 core:Non-currentFinancialInstruments 2024-07-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14995409
England and Wales

 

 

 


Unaudited Financial Statements

for the year ended 31 July 2025

for

MONMOUTHPHARMA LTD

 
 
 
£
2025
£
   
£
2024
£
Current assets 20  7,833 
Creditors: amount falling due within one year (891) (5,514)
Net current assets/(liabilities) (871) 2,319 
Total assets less current liabilities (871) 2,319 
Creditors: amount falling due after more than one year (1,499)
Net assets/(liabilities) (2,370) 2,319 
 
Capital and reserves (2,370) 2,319 
 



Notes to the Accounts
Statutory Information
Monmouthpharma Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number 14995409, registration address 19 Sandhurst Road, London, SE6 1UP, England.

The presentation currency is £ sterling.
1.

Accounting Policies

Basis of accounting
The financial statements are prepared under the historical cost convention and in accordance with the FRS 105 Financial Reporting Standard for Micro Entities (effective January 2016).
2.

Average number of employees

Average number of employees during the year was 0 (2024: 0).

Director's Responsibilities:
  1. For the year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
  2. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.
  3. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The financial statements have been prepared in accordance with the micro-entity provisions.

Signed on behalf of the board of directors:


---------------------------------------------
Gavyn Barrett
Director

Date approved: 29 July 2026
1